Lazar-Poloczek, E.; Romuk, E.; Jacheć, W.; Stanek, W.; Stanek, B.; Szołtysik, M.; Techmański, T.; Hasterok, M.; Wojciechowska, C.
Levels of TNF-α and Soluble TNF Receptors in Normal-Weight, Overweight and Obese Patients with Dilated Non-Ischemic Cardiomyopathy: Does Anti-TNF Therapy Still Have Potential to Be Used in Heart Failure Depending on BMI? Biomedicines 2022, 10, 2959.
https://doi.org/10.3390/biomedicines10112959
AMA Style
Lazar-Poloczek E, Romuk E, Jacheć W, Stanek W, Stanek B, Szołtysik M, Techmański T, Hasterok M, Wojciechowska C.
Levels of TNF-α and Soluble TNF Receptors in Normal-Weight, Overweight and Obese Patients with Dilated Non-Ischemic Cardiomyopathy: Does Anti-TNF Therapy Still Have Potential to Be Used in Heart Failure Depending on BMI? Biomedicines. 2022; 10(11):2959.
https://doi.org/10.3390/biomedicines10112959
Chicago/Turabian Style
Lazar-Poloczek, Elżbieta, Ewa Romuk, Wojciech Jacheć, Wiktoria Stanek, Bartosz Stanek, Monika Szołtysik, Tomasz Techmański, Maja Hasterok, and Celina Wojciechowska.
2022. "Levels of TNF-α and Soluble TNF Receptors in Normal-Weight, Overweight and Obese Patients with Dilated Non-Ischemic Cardiomyopathy: Does Anti-TNF Therapy Still Have Potential to Be Used in Heart Failure Depending on BMI?" Biomedicines 10, no. 11: 2959.
https://doi.org/10.3390/biomedicines10112959
APA Style
Lazar-Poloczek, E., Romuk, E., Jacheć, W., Stanek, W., Stanek, B., Szołtysik, M., Techmański, T., Hasterok, M., & Wojciechowska, C.
(2022). Levels of TNF-α and Soluble TNF Receptors in Normal-Weight, Overweight and Obese Patients with Dilated Non-Ischemic Cardiomyopathy: Does Anti-TNF Therapy Still Have Potential to Be Used in Heart Failure Depending on BMI? Biomedicines, 10(11), 2959.
https://doi.org/10.3390/biomedicines10112959
